MYMD / MyMD Pharmaceuticals, Inc. - Pengajuan SECLaporan Tahunan, Pernyataan Proksi

Membership Interest Purchase Agreement by and between LPU HOLDINGS LLC (the “Company”) TNF PHARMACEUTICALS, INC. (“Buyer”), with the Members of the Company joining solely for purposes of Article V Dated as of September 2, 2025 Membership Interest Pur

Exhibit 10.1 Execution Version Membership Interest Purchase Agreement by and between LPU HOLDINGS LLC (the “Company”) and TNF PHARMACEUTICALS, INC. (“Buyer”), with the Members of the Company joining solely for purposes of Article V Dated as of September 2, 2025 Membership Interest Purchase Agreement This Membership Interest Purchase Agreement (this “Agreement”), dated as of September 2, 2025, is e

STOCKHOLDER VOTING AGREEMENT

Exhibit 10.2 STOCKHOLDER VOTING AGREEMENT THIS STOCKHOLDER VOTING AGREEMENT (this “Agreement”) is made and entered into as of September 4, 2025, by and among TNF Pharmaecuticals, Inc. (the “Company”) and each of the undersigned Stockholders of the Company (the “Stockholders”). RECITALS A. WHEREAS, on September 2, 2025, the Stockholders and the Company entered into a Member Interest Purchase Agreem

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 2, 2025 TNF Pharmaceu

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 2, 2025 TNF Pharmaceuticals, Inc. (Exact name of Registrant as specified in its charter) Delaware 001-36268 22-2983783 (State or other jurisdiction of incorporation) (Comm

TECHNOLOGY LICENSE AND DEVELOPMENT AGREEMENT

Exhibit 10.4 TECHNOLOGY LICENSE AND DEVELOPMENT AGREEMENT This Technology License and Development Agreement (the “Agreement”) is made and entered into as of September 2, 2025 (subject to Section 10.1, the “Effective Date”), by and among LightSolver Ltd., an Israeli company with its principal place of business at Yigal Alon 94b, 14th floor, Tel Aviv, Israel (“LightSolver” or “LS”); and LPU Holdings

REGISTRATION RIGHTS AGREEMENT

Exhibit 10.3 REGISTRATION RIGHTS AGREEMENT THIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of [ ], 2025 (the “Execution Date”), is entered into by and between TNF Pharmaceuticals, Inc., a Delaware corporation (the “Company”) and LPU Holdings LLC (“LPU”) and the sellers (each, individually, a “Seller,” and collectively, “Sellers”) identified on the signature pages to that certain Me

SECURITIES PURCHASE AGREEMENT

Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of September 2, 2025, is by and among TNF Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and each of the investors listed on the Schedule of Buyers attached hereto (individually, a “Buyer” and collectively, the “Buyers”). RECITALS A. The Company has authorized a new series of c

TNF Pharmaceuticals Announces Reverse Stock Split For Nasdaq Listing Compliance

Exhibit 99.2 TNF Pharmaceuticals Announces Reverse Stock Split For Nasdaq Listing Compliance New York, NY — August 28, 2025 — TNF Pharmaceuticals, Inc. (Nasdaq: TNFA) (“TNF” or the “Company”), a clinical stage biopharmaceutical company committed to developing novel therapies for autoimmune and inflammatory conditions, today announced that its board of directors has authorized a reverse stock split

TNF PHARMACEUTICALS, INC. Warrant To Purchase Common Stock

Exhibit 4.1 NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE EXERCISABLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR T

AMENDED AND RESTATED CERTIFICATE OF DESIGNATIONS OF SERIES F-1 CONVERTIBLE PREFERRED STOCK OF TNF PHARMACEUTICALS, INC.

Exhibit 3.3 AMENDED AND RESTATED CERTIFICATE OF DESIGNATIONS OF SERIES F-1 CONVERTIBLE PREFERRED STOCK OF TNF PHARMACEUTICALS, INC. This Amended and Restated Certificate of Designations of Series F-1 Convertible Preferred Stock (this “Amended and Restated Certificate of Designations”) is dated as of [ ], 2025 (the “Effective Date”); WHEREAS, the board of directors (the “Board”) of TNF Pharmaceutic

REGISTRATION RIGHTS AGREEMENT

Exhibit 10.2 REGISTRATION RIGHTS AGREEMENT This REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of September 2, 2025, is by and among TNF Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and the undersigned buyers (each, a “Buyer,” and collectively, the “Buyers”). RECITALS A. In connection with the Securities Purchase Agreement by and among the parties hereto, dated as of

CERTIFICATE OF DESIGNATIONS OF SERIES H CONVERTIBLE PREFERRED STOCK OF TNF PHARMACEUTICALS, INC.

Exhibit 3.1 CERTIFICATE OF DESIGNATIONS OF SERIES H CONVERTIBLE PREFERRED STOCK OF TNF PHARMACEUTICALS, INC. I, Joshua Silverman, hereby certify that I am the Executive Chairman of TNF Pharmaceuticals, Inc. (the “Company”), a corporation organized and existing under the Delaware General Corporation Law (the “DGCL”), and further do hereby certify: That pursuant to the authority expressly conferred

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 28, 2025 TNF Pharmaceutica

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 28, 2025 TNF Pharmaceuticals, Inc. (Exact name of Registrant as specified in its charter) Delaware 001-36268 22-2983783 (State or other jurisdiction of incorporation) (Commissi

CERTIFICATE OF AMENDMENT CERTIFICATE OF INCORPORATION TNF Pharmaceuticals, Inc.

Exhibit 3.4 CERTIFICATE OF AMENDMENT Of CERTIFICATE OF INCORPORATION OF TNF Pharmaceuticals, Inc. TNF Pharmaceuticals, Inc. (the “Corporation”), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware, does hereby certify that: 1. The Certificate of Incorporation of the Corporation (as amended, the “Certificate of Incorporation”) was filed w

OMNIBUS Amendment AGREEMENT

Exhibit 10.3 OMNIBUS Amendment AGREEMENT This Omnibus Amendment Agreement (this “Agreement”), dated as of September 2, 2025, is by and between TNF Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and the investor listed on the signature page attached hereto (the “Investor”). WITNESSETH Whereas, the Company and the Investor are party to that certain Securities Purchase Agreement, date

TNF Pharmaceuticals Secures Exclusive Global Rights to Innovative Light Speed Computing Accelerator for Use in Cryptocurrency Applications First light- and laser-based computing system designed to outperform quantum and supercomputing and solve compl

Exhibit 99.1 TNF Pharmaceuticals Secures Exclusive Global Rights to Innovative Light Speed Computing Accelerator for Use in Cryptocurrency Applications First light- and laser-based computing system designed to outperform quantum and supercomputing and solve complex problems unfeasible for GPUs Strategic partner LightSolver named a 2025 World Economic Forum Technology Pioneer and recognized in Gart

SECOND AMENDED AND RESTATED CERTIFICATE OF DESIGNATIONS OF SERIES F CONVERTIBLE PREFERRED STOCK OF TNF PHARMACEUTICALS, INC. PURSUANT TO SECTION 242 OF THE DELAWARE GENERAL CORPORATION LAW

Exhibit 3.2 SECOND AMENDED AND RESTATED CERTIFICATE OF DESIGNATIONS OF SERIES F CONVERTIBLE PREFERRED STOCK OF TNF PHARMACEUTICALS, INC. PURSUANT TO SECTION 242 OF THE DELAWARE GENERAL CORPORATION LAW This Second Amended and Restated Certificate of Designations of Series F Convertible Preferred Stock (this “Amended and Restated Certificate of Designations”) is dated as of [ ], 2025 (the “Effective

Certificate of Amendment of Amended and Restated Certificate of Designations of Series F Convertible Preferred Stock.

Exhibit 3.2 CERTIFICATE OF AMENDMENT OF CERTIFICATE OF DESIGNATIONS OF SERIES F CONVERTIBLE PREFERRED STOCK OF TNF PHARMACEUTICALS, INC. PURSUANT TO SECTION 242 OF THE DELAWARE GENERAL CORPORATION LAW This Certificate of Amendment to the Certificate of Designations of Series F Convertible Preferred Stock (the “Amendment”) is dated as of August 19, 2025. WHEREAS, the board of directors (the “Board”

Form of Omnibus Amendment Agreement, dated August 19, 2025, by and between TNF Pharmaceuticals, Inc. and the investors party thereto.

Exhibit 10.1 OMNIBUS Amendment AGREEMENT This Omnibus Amendment Agreement (this “Agreement”), dated as of August 19, 2025, is by and between TNF Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and the investor listed on the signature page attached hereto (the “Investor”). WITNESSETH Whereas, the Company and the Investor are party to that certain Securities Purchase Agreement, dated

Certificate of Amendment of Certificate of Designations of Series F-1 Convertible Preferred Stock.

Exhibit 3.1 CERTIFICATE OF AMENDMENT OF CERTIFICATE OF DESIGNATIONS OF SERIES F-1 CONVERTIBLE PREFERRED STOCK OF TNF PHARMACEUTICALS, INC. PURSUANT TO SECTION 242 OF THE DELAWARE GENERAL CORPORATION LAW This Certificate of Amendment to the Certificate of Designations of Series F-1 Convertible Preferred Stock (the “Amendment”) is dated as of August 19, 2025. WHEREAS, the board of directors (the “Bo

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36268 TNF Pharma

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR For Period Ended: June 30, 2025 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Report on Form 10-Q For the Transition Period

CERTIFICATE OF AMENDMENT CERTIFICATE OF INCORPORATION TNF Pharmaceuticals, Inc.

Exhibit 3.1 CERTIFICATE OF AMENDMENT Of CERTIFICATE OF INCORPORATION OF TNF Pharmaceuticals, Inc. TNF Pharmaceuticals, Inc. (the “Corporation”), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware, does hereby certify that: 1. The name of the Corporation is TNF Pharmaceuticals, Inc. 2. The Certificate of Incorporation of this Corporation

Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Material Modification to Rights of Security Holders, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 3, 2025 TNF Pharmaceuticals, Inc. (Exact name of Registrant as specified in its charter) Delaware 001-36268 22-2983783 (State or other jurisdiction of incorporation) (Commission

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36268 TNF Pharm

First Amendment to the Bylaws of TNF Pharmaceuticals, Inc.

Exhibit 3.1 FIRST AMENDMENT TO THE BYLAWS OF TNF PHARMACEUTICALS, INC. Pursuant to Article VIII of the Certificate of Incorporation, as amended, of TNF Pharmaceuticals, Inc., a Delaware corporation (the “Corporation”), Article X of the Bylaws (the “Bylaws”) of the Corporation, and Section 109 of the General Corporation Law of the State of Delaware, on the date hereof, the Bylaws of the Corporation

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2025 TNF Pharmaceuticals,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2025 TNF Pharmaceuticals, Inc. (Exact name of Registrant as specified in its charter) Delaware 001-36268 22-2983783 (State or other jurisdiction of incorporation) (Commission F

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State

Certificate of Amendment of Amended and Restated Certificate of Designations of Series F Convertible Preferred Stock.

Exhibit 3.5.3 CERTIFICATE OF AMENDMENT OF CERTIFICATE OF DESIGNATIONS OF SERIES F CONVERTIBLE PREFERRED STOCK OF TNF PHARMACEUTICALS, INC. PURSUANT TO SECTION 242 OF THE DELAWARE GENERAL CORPORATION LAW This Certificate of Amendment to the Certificate of Designations of Series F Convertible Preferred Stock (the “Amendment”) is dated as of April 8, 2025. WHEREAS, the board of directors (the “Board”

TNF Pharmaceuticals, Inc. Insider Trading Policy.

Exhibit 19.1 Insider Trading This statement sets forth the policies of TNF Pharmaceuticals on trading and causing the trading of securities while in possession of material non-public information. Sections 1 through 3 and Section 5 applies to all persons associated with the Corporation including consultants. The entire policy applies to the following “Covered Persons”: (i) all directors of the Corp

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State

Certificate of Amendment of Certificate of Designations of Series F-1 Convertible Preferred Stock.

Exhibit 3.6.1 CERTIFICATE OF AMENDMENT OF CERTIFICATE OF DESIGNATIONS OF SERIES F-1 CONVERTIBLE PREFERRED STOCK OF TNF PHARMACEUTICALS, INC. PURSUANT TO SECTION 242 OF THE DELAWARE GENERAL CORPORATION LAW This Certificate of Amendment to the Certificate of Designations of Series F-1 Convertible Preferred Stock (the “Amendment”) is dated as of April 8, 2025. WHEREAS, the board of directors (the “Bo

Form of Omnibus Amendment Agreement, dated March 30, 2025, by and between TNF Pharmaceuticals, Inc. and the investors party thereto.

Exhibit 10.45 OMNIBUS Amendment AGREEMENT This Omnibus Amendment Agreement (this “Agreement”), dated as of April 8, 2025, is by and between TNF Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and the investor listed on the signature page attached hereto (the “Investor”). WITNESSETH Whereas, the Company and the Investor are party to that certain Securities Purchase Agreement, dated a

Shareholder Director Nominations

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 10, 2025 TNF Pharmaceuticals, Inc. (Exact name of Registrant as specified in its charter) Delaware 001-36268 22-2983783 (State or other jurisdiction of incorporation) (Commissio

Description of Securities.

Exhibit 4.1 DESCRIPTION OF SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXHANGE ACT OF 1934, AS AMENDED This description of the capital stock of TNF Pharmaceuticals, Inc., a Delaware corporation (“we,” “our” and the “Company”) is intended as a summary and is qualified in its entirety by reference to our Certificate of Incorporation (the “Certificate of Incorporation”) and the Byl

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36268 TNF Pharmaceutica

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one): ☒ Form 10-K ☐ Form 20-F ☐ Form 11-K ☐ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR For Period Ended: December 31, 2024 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Report on Form 10-Q For the Transition Pe

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 17, 2025 TNF Pharmaceuticals, Inc. (Exact name of Registrant as specified in its charter) Delaware 001-36268 22-2983783 (State or other jurisdiction of incorporation) (Commissio

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 6, 2025 TNF Pharmaceuticals, Inc. (Exact name of Registrant as specified in its charter) Delaware 001-36268 22-2983783 (State or other jurisdiction of incorporation) (Commission

Transcript of Conference Call, held March 6, 2025.

Exhibit 10.1 TNF Pharmaceuticals Investor Update Conference Call March 6, 2025 Presenters Mitchell Glass - Director, President and Chief Medical Officer Operator Good afternoon, everyone, and welcome to the TNF Pharmaceuticals Investor Conference call and Clinical Scientific Update. Today’s call will be conducted by the Company’s President and Chief Medical Officer, Dr. Mitchell Glass. Before I tu

Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 25, 2024 TNF Pharmaceuticals, Inc. (Exact name of Registrant as specified in its charter) Delaware 001-36268 22-2983783 (State or other jurisdiction of incorporation) (Commis

First Amendment to the TNF Pharmaceuticals, Inc. 2021 Equity Incentive Plan

Exhibit 10.1 FIRST AMENDMENT TO TNF Pharmaceuticals, Inc. 2021 Equity Incentive Plan This FIRST AMENDMENT TO TNF Pharmaceuticals, Inc. 2021 Equity Incentive Plan (this “Amendment”), effective as of November 1, 2024, is made and entered into by TNF Pharmaceuticals, Inc., a Delaware corporation (the “Company”). Terms used in this Amendment with initial capital letters that are not otherwise defined

TNFA / TNF Pharmaceuticals, Inc. / Global X Management CO LLC - SC 13G/A Passive Investment

SC 13G/A 1 ef20038672sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G INFORMATION STATEMENT TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1 (b) (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2 (b) (Amendment No. 1)* TNF Pharmaceuticals, Inc. (Name of Issuer) Common Shares (Title of Class of Securities) 62856X201 (CUS

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36268 TNF P

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State

TNF Pharmaceuticals Announces Strategic Equity Investment Priced at a Premium to Market Prevail Partners, LLC investment priced at 40% premium to market Prevail InfoWorks, Inc. to act as Clinical Research Organization partner; global full service CRO

Exhibit 99.1 TNF Pharmaceuticals Announces Strategic Equity Investment Priced at a Premium to Market Prevail Partners, LLC investment priced at 40% premium to market Prevail InfoWorks, Inc. to act as Clinical Research Organization partner; global full service CRO with hundreds of clinical trials over a decade TNF Pharmaceuticals fully funded for clinical trials for next two years BALTIMORE — Octob

Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 1, 2024 TNF Pharmaceuticals, Inc. (Exact name of Registrant as specified in its charter) Delaware 001-36268 22-2983783 (State or other jurisdiction of incorporation) (Commissi

Stock Purchase Agreement, dated as of October 1, 2024, by and between TNF Pharmaceuticals, Inc. and Prevail Partners, LLC (incorporated herein by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on October 7, 2024).

Exhibit 10.1 STOCK PURCHASE AGREEMENT This Stock Purchase Agreement (“Agreement”) is made and entered into as of October 1, 2024 (“Effective Date”), between TNF Pharmaceuticals, Inc. (the “Company”) and Prevail Partners, LLC (“Prevail Partners”), Tax ID# 27-0256095. The Company and Prevail Partners are collectively referred to herein as the “Parties.” WITNESSETH WHEREAS, the Company identifies and

Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 30, 2024 TNF Pharmaceuticals, Inc. (Exact name of Registrant as specified in its charter) Delaware 001-36268 22-2983783 (State or other jurisdiction of incorporation) (Commi

Letter dated October 4, 2024 from Morison Cogen LLP to the U.S. Securities and Exchange Commission.

Exhibit 16.1 October 4, 2024 Securities and Exchange Commission 100 F Street NE Washington, DC 20549 Ladies and Gentlemen: We have been furnished with a copy of the response to Item 4.01 of Form 8-K for the event that occurred on September 30, 2024, to be filed by our former client, TNF Pharmaceuticals, Inc. (formerly MyMD Pharmaceuticals, Inc.). We agree with the statements made in response to th

TNF Pharmaceuticals, Inc. 855 N. Wolfe Street, Suite 623 Baltimore, MD

TNF Pharmaceuticals, Inc. 855 N. Wolfe Street, Suite 623 Baltimore, MD September 30, 2024 VIA EDGAR Division of Corporation Finance Office of Life Sciences U.S. Securities and Exchange Commission Washington, D.C. 20549 Attention: Doris Stacey Gama and Suzanne Hayes Re: TNF Pharmaceuticals, Inc. Annual Report on Form 10-K for fiscal year ended December 31, 2023 Originally filed on April 1, 2024 Fil

Shareholder Director Nominations

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 20, 2024 TNF Pharmaceuticals, Inc. (Exact name of Registrant as specified in its charter) Delaware 001-36268 22-2983783 (State or other jurisdiction of incorporation) (Commi

Form of Amendment to Series F-1 Short Term Warrant.

Exhibit 4.7 Amendment This Amendment (this “Amendment”), dated as of August [ ], 2024, is by and among TNF Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and the investor listed on the signature page attached hereto (the “Investor”). WITNESSETH Whereas, the Company and the Investor are party to that certain Securities Purchase Agreement, dated as of May 20, 2024 (the “Purchase Agre

Form of Amendment to Series G Long Term Warrant.

Exhibit 4.8 Amendment This Amendment (this “Amendment”), dated as of August [ ], 2024, is by and among TNF Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and the investor listed on the signature page attached hereto (the “Investor”). WITNESSETH Whereas, the Company and the Investor are party to that certain Securities Purchase Agreement, dated as of May 20, 2024 (the “Purchase Agre

Form of Amendment to Series F-1 Long Term Warrant.

Exhibit 4.6 Amendment This Amendment (this “Amendment”), dated as of August [ ], 2024, is by and among TNF Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and the investor listed on the signature page attached hereto (the “Investor”). WITNESSETH Whereas, the Company and the Investor are party to that certain Securities Purchase Agreement, dated as of May 20, 2024 (the “Purchase Agre

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36268 TNF Pharma

Form of Amendment to Series G Short Term Warrant.

Exhibit 4.9 Amendment This Amendment (this “Amendment”), dated as of August [ ], 2024, is by and among TNF Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and the investor listed on the signature page attached hereto (the “Investor”). WITNESSETH Whereas, the Company and the Investor are party to that certain Securities Purchase Agreement, dated as of May 20, 2024 (the “Purchase Agre

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR For Period Ended: June 30, 2024 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Report on Form 10-Q For the Transition Period

Certificate of Amendment of Certificate of Designations of Series G Convertible Preferred Stock.

Exhibit 3.1 Certificate of Amendment of Certificate of Designations of Series G Convertible Preferred Stock of TNF PHARMACEUTICALS, INC. Pursuant to Section 242 of the Delaware General Corporation Law This Certificate of Amendment to the Certificate of Designations of Series G Convertible Preferred Stock (the “Amendment”) is dated as of August 8, 2024. WHEREAS, the board of directors (the “Board”)

Form of Amendment Agreement, dated as of August 8, 2024, by and among TNF Pharmaceuticals, Inc. and the investors party thereto.

Exhibit 10.1 Amendment AGREEMENT This Amendment Agreement (this “Agreement”), dated as of August 8, 2024, is by and between TNF Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and the investor listed on the signature page attached hereto (the “Investor”). WITNESSETH Whereas, the Company and the Investor are party to that certain Securities Purchase Agreement, dated as of May 20, 202

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2024 TNF Pharmaceutical

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2024 TNF Pharmaceuticals, Inc. (Exact name of Registrant as specified in its charter) Delaware 001-36268 22-2983783 (State or other jurisdiction of incorporation) (Commissio

TNF Pharmaceuticals, Inc. 65,117,652 Shares of Common Stock (and up to 4,500,000 Dividend Shares)

Filed Pursuant to Rule 424(b)(3) Registration No. 333-280415 PROSPECTUS TNF Pharmaceuticals, Inc. 65,117,652 Shares of Common Stock (and up to 4,500,000 Dividend Shares) This prospectus relates to the resale by the selling stockholders named in this prospectus from time to time of up to an aggregate of 69,617,652 shares of our common stock, par value $0.001 per share (the “Common Stock”), issuable

TNF Pharmaceuticals, Inc. 855 N. Wolfe Street, Suite 623 Baltimore, MD 21205

TNF Pharmaceuticals, Inc. 855 N. Wolfe Street, Suite 623 Baltimore, MD 21205 August 9, 2024 VIA EDGAR Division of Corporation Finance Office of Life Sciences U.S. Securities and Exchange Commission Washington, D.C. 20549 Attention: Tamika Sheppard Re: TNF Pharmaceuticals, Inc. (f/k/a MyMD Pharmaceuticals, Inc.) Registration Statement on Form S-3 Originally filed on June 21, 2024, as amended on Aug

Filing Fee Table.

Exhibit 107 Calculation of Filing Fee Tables Form S-3 TNF Pharmaceuticals, Inc. Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered (1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forw

As Filed with the Securities and Exchange Commission on August 8, 2024

As Filed with the Securities and Exchange Commission on August 8, 2024 Registration No.

Certificate of Amendment of Certificate of Incorporation of TNF Pharmaceuticals, Inc (incorporated herein by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on July 26, 2024).

Exhibit 3.1 Certificate of Amendment of Certificate of Incorporation of MYMD PHARMACEUTICALS, INC. MyMD Pharmaceuticals, Inc., a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the “Corporation”) hereby certifies: 1. The original Certificate of Incorporation of the Corporation was filed with the Secretary of State of Delaware on Octob

Regulation FD Disclosure, Financial Statements and Exhibits, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 22, 2024 TNF Pharmaceuticals, Inc. (Exact name of Registrant as specified in its charter) Delaware 001-36268 22-2983783 (State or other jurisdiction of incorporation) (Commission

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 24, 2024 TNF Pharmaceuticals

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 24, 2024 TNF Pharmaceuticals, Inc. (Exact name of Registrant as specified in its charter) Delaware 001-36268 22-2983783 (State or other jurisdiction of incorporation) (Commission

TNF Pharmaceuticals (Formerly MyMD Pharmaceuticals) Begins Trading Under New Nasdaq Stock Symbol “TNFA” Effective Before Market Open Today New name and stock symbol represents therapeutic focus on inhibiting TNF-alpha to regulate the immuno-metabolic

Exhibit 99.2 TNF Pharmaceuticals (Formerly MyMD Pharmaceuticals) Begins Trading Under New Nasdaq Stock Symbol “TNFA” Effective Before Market Open Today New name and stock symbol represents therapeutic focus on inhibiting TNF-alpha to regulate the immuno-metabolic system BALTIMORE — July 24, 2024 — TNF Pharmaceuticals, Inc. (Nasdaq: TNFA) (formerly MyMD Pharmaceuticals, Inc.) (the “Company”), a cli

Certificate of Amendment of Certificate of Incorporation of TNF Pharmaceuticals, Inc (incorporated herein by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on July 26, 2024).

Exhibit 3.1 CERTIFICATE OF AMENDMENT Of CERTIFICATE OF INCORPORATION OF TNF Pharmaceuticals, Inc. TNF Pharmaceuticals, Inc. (the “Corporation”), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware, does hereby certify that: 1. The name of the Corporation is TNF Pharmaceuticals, Inc. 2. The Certificate of Incorporation of this Corporation

MyMD Pharmaceuticals Announces Corporate Rebranding to New Name TNF Pharmaceuticals, Inc. New name represents therapeutic focus on inhibiting TNF-alpha to regulate the immuno-metabolic system Company plans mid-stage clinical trials of TNF-alpha inhib

Exhibit 99.1 MyMD Pharmaceuticals Announces Corporate Rebranding to New Name TNF Pharmaceuticals, Inc. New name represents therapeutic focus on inhibiting TNF-alpha to regulate the immuno-metabolic system Company plans mid-stage clinical trials of TNF-alpha inhibitor drug MYMD-1® following statistically significant Phase 2 studies TNF Pharmaceuticals will begin trading on Nasdaq under the new trad

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State

Certificate of Amendment of Certificate of Designations of Series G Convertible Preferred Stock (incorporated herein by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on June 24, 2024).

Exhibit 3.1 Certificate of Amendment of Certificate of Designations of Series G Convertible Preferred Stock of MyMD PHARMACEUTICALS, INC. Pursuant to Section 242 of the Delaware General Corporation Law This Certificate of Amendment to the Certificate of Designations of Series G Convertible Preferred Stock (the “Amendment”) is dated as of June 17, 2024. WHEREAS, the board of directors (the “Board”)

Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 17, 2024 MyMD Pharmaceuticals, Inc. (Exact name of Registrant as specified in its charter) Delaware 001-36268 22-2983783 (State or other jurisdiction of incorporation) (Commissio

As Filed with the Securities and Exchange Commission on June 21, 2024

As Filed with the Securities and Exchange Commission on June 21, 2024 Registration No.

Filing Fee Table.

Exhibit 107 Calculation of Filing Fee Tables Form S-3 MyMD Pharmaceuticals, Inc. Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered (1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry For

Entry into a Material Definitive Agreement

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 20, 2024 MyMD Pharmaceuticals, Inc. (Exact name of Registrant as specified in its charter) Delaware 001-36268 22-2983783 (State or other jurisdiction of incorp

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State

MyMD Pharmaceuticals Appoints Accomplished Biopharmaceutical Leader and Current Board Member, Mitchell Glass, M.D. as President and Chief Medical Officer

Exhibit 99.1 MyMD Pharmaceuticals Appoints Accomplished Biopharmaceutical Leader and Current Board Member, Mitchell Glass, M.D. as President and Chief Medical Officer ● Dr. Glass brings a 35-year career in life sciences with multiple drug approvals including Accolate ®, Avandia ® and Coreg® ● Dr. Glass brings broad expertise in regulatory strategies: 5 NDAs and MAAs, 7 pre-NDA meetings, 12 End of

Certificate of Amendment of Certificate of Designations of Series G Convertible Preferred Stock.

Exhibit 3.1 Certificate of Amendment of Certificate of Designations of Series G Convertible Preferred Stock of MyMD PHARMACEUTICALS, INC. Pursuant to Section 242 of the Delaware General Corporation Law This Certificate of Amendment to the Certificate of Designations of Series G Convertible Preferred Stock (the “Amendment”) is dated as of June [ ], 2024. WHEREAS, the board of directors (the “Board”

General Release and Severance Agreement, by and between MyMD Pharmaceuticals, Inc. and Christopher Chapman, dated as of June 14, 2024

Exhibit 10.2 GENERAL RELEASE AND SEVERANCE AGREEMENT This General Release and Severance Agreement (the “Agreement”), dated as of June 14 2024 is made and entered into by and between Chris Chapman, M.D. (“Employee”) and MyMD Pharmaceuticals, Inc. (the “Company”). For good and valuable consideration, receipt of which is hereby acknowledged, in order to effect a mutually satisfactory and amicable sep

Form of Amendment Agreement, dated as of June 17, 2024, by and among MyMD Pharmaceuticals, Inc. and the investors party thereto.

Exhibit 10.1 Amendment AGREEMENT This Amendment Agreement (this “Agreement”), dated as of June 17, 2024, is by and between MyMD Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and the investor listed on the signature page attached hereto (the “Investor”). WITNESSETH Whereas, the Company and the Investor are party to that certain Securities Purchase Agreement, dated as of May 20, 202

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Entry into a Material Definitive Agreement, Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 13, 2024 MyMD Pharmaceuticals, Inc. (Exact name of Registrant as specified in its charter) Delaware 001-36268 22-2983783 (State or other jurisdiction of incorporation) (Commissio

MYMD / MyMD Pharmaceuticals, Inc. / PharmaCyte Biotech, Inc. - SCHEDULE 13D Activist Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 Amendment No. )* MyMD Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 62856X102 (CUSIP Number) Carlos Trujillo c/o PharmaCyte Biotech, Inc. 3960 Howard Hughes Parkway, Suite 500 Las Vegas, Nevada 89169 (917) 595-2850 (Name,

Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 21, 2024 MyMD Pharmaceuticals, Inc. (Exact name of Registrant as specified in its charter) Delaware 001-36268 22-2983783 (State or other jurisdiction of incorporation) (Commission

Certificate of Designations of Series F-1 Convertible Preferred Stock (incorporated herein by reference to Exhibit 3.2 to the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on May 23, 2024).

Exhibit 3.2 CERTIFICATE OF DESIGNATIONS OF SERIES F-1 CONVERTIBLE PREFERRED STOCK OF MyMD PHARMACEUTICALS, INC. I, Christopher Chapman, M.D., hereby certify that I am the President of MyMD Pharmaceuticals, Inc. (the “Company”), a corporation organized and existing under the Delaware General Corporation Law (the “DGCL”), and further do hereby certify: That pursuant to the authority expressly confer

Certificate of Designations of Series G Convertible Preferred Stock (incorporated herein by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on May 23, 2024).

Exhibit 3.1 CERTIFICATE OF DESIGNATIONS OF SERIES G CONVERTIBLE PREFERRED STOCK OF MyMD PHARMACEUTICALS, INC. I, Christopher Chapman, M.D., hereby certify that I am the President of MyMD Pharmaceuticals, Inc. (the “Company”), a corporation organized and existing under the Delaware General Corporation Law (the “DGCL”), and further do hereby certify: That pursuant to the authority expressly conferre

Form of Series G Long-Term Warrant (incorporated herein by reference to Exhibit 4.1 to the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on May 21, 2024).

Exhibit 4.1 NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE EXERCISABLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR T

Form of Series G Purchase Agreement (incorporated herein by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on May 21, 2024).

Exhibit 10.1 Securities Purchase Agreement This Securities Purchase Agreement (the “Agreement”), dated as of May 20, 2024, is by and among MyMD Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and each of the investors listed on the Schedule of Buyers attached hereto (individually, a “Buyer” and collectively, the “Buyers”). RECITALS A. The Company and each Buyer is executing and deli

MyMD Pharmaceuticals Secures Strategic Investments Up to $42 Million in Two-Part Funding from New Strategic Investor and Existing Shareholders with Committed Closing of an Aggregate of $14 Million Up Front

Exhibit 99.1 MyMD Pharmaceuticals Secures Strategic Investments Up to $42 Million in Two-Part Funding from New Strategic Investor and Existing Shareholders with Committed Closing of an Aggregate of $14 Million Up Front BALTIMORE — May 21, 2024 — MyMD Pharmaceuticals, Inc.® (Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage biopharmaceutical company committed to developing novel therapies f

Form of Series F-1 Long-Term Warrant (incorporated herein by reference to Exhibit 4.3 to the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on May 21, 2024).

Exhibit 4.3 NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE EXERCISABLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR T

Form of Series G Registration Rights Agreement (incorporated herein by reference to Exhibit 10.3 to the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on May 21, 2024).

Exhibit 10.3 REGISTRATION RIGHTS AGREEMENT This REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of May 20, 2024, is by and among MyMD Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and the undersigned buyers (each, a “Buyer,” and collectively, the “Buyers”). RECITALS A. In connection with the Securities Purchase Agreement by and among the parties hereto, dated as of May

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 20, 2024 MyMD Pharmaceuticals

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 20, 2024 MyMD Pharmaceuticals, Inc. (Exact name of Registrant as specified in its charter) Delaware 001-36268 22-2983783 (State or other jurisdiction of incorporation) (Commission

Form of Certificate of Designations of Series G Convertible Preferred Stock.

Exhibit 3.1 CERTIFICATE OF DESIGNATIONS OF SERIES G CONVERTIBLE PREFERRED STOCK OF MyMD PHARMACEUTICALS, INC. I, Christopher Chapman, M.D., hereby certify that I am the President of MyMD Pharmaceuticals, Inc. (the “Company”), a corporation organized and existing under the Delaware General Corporation Law (the “DGCL”), and further do hereby certify: That pursuant to the authority expressly conferre

Form of Series F-1 Purchase Agreement (incorporated herein by reference to Exhibit 10.2 to the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on May 21, 2024).

Exhibit 10.2 Securities Purchase Agreement This Securities Purchase Agreement (the “Agreement”), dated as of May 20, 2024, is by and among MyMD Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and each of the investors listed on the Schedule of Buyers attached hereto (individually, a “Buyer” and collectively, the “Buyers”). RECITALS A. The Company and each Buyer is executing and deli

Form of Omnibus Waiver, Consent, Notice and Amendment, by and among MyMD Pharmaceuticals, Inc. and the investors party thereto.

Exhibit 10.5 Omnibus Waiver, Consent, Notice and Amendment This Omnibus Waiver, Consent and Amendment (this “Agreement”), dated as of May 20, 2024, is by and among MyMD Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and the investor listed on the signature page attached hereto (the “Investor”). WITNESSETH Whereas, the Company and the Investor are party to that certain Securities Pu

Form of Certificate of Designations of Series F-1 Convertible Preferred Stock.

Exhibit 3.2 CERTIFICATE OF DESIGNATIONS OF SERIES F-1 CONVERTIBLE PREFERRED STOCK OF MyMD PHARMACEUTICALS, INC. I, Christopher Chapman, M.D., hereby certify that I am the President of MyMD Pharmaceuticals, Inc. (the “Company”), a corporation organized and existing under the Delaware General Corporation Law (the “DGCL”), and further do hereby certify: That pursuant to the authority expressly confer

Form of Series F-1 Registration Rights Agreement (incorporated herein by reference to Exhibit 10.4 to the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on May 21, 2024).

Exhibit 10.4 REGISTRATION RIGHTS AGREEMENT This REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of May 20, 2024, is by and among MyMD Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and the undersigned buyers (each, a “Buyer,” and collectively, the “Buyers”). RECITALS A. In connection with the Securities Purchase Agreement by and among the parties hereto, dated as of May

Form of Series G Short-Term Warrant (incorporated herein by reference to Exhibit 4.2 to the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on May 21, 2024).

Exhibit 4.2 NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE EXERCISABLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR T

Form of Series F-1 Short-Term Warrant (incorporated herein by reference to Exhibit 4.4 to the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on May 21, 2024).

Exhibit 4.4 NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE EXERCISABLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR T

Certificate of Amendment of Amended and Restated Certificate of Designations of Series F Convertible Preferred Stock of MyMD Pharmaceuticals, Inc. (incorporated herein by reference to Exhibit 3.3 to the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on May 21, 2024).

Exhibit 3.3 CERTIFICATE OF AMENDMENT OF AMENDED AND RESTATED CERTIFICATE OF DESIGNATIONS OF SERIES F CONVERTIBLE PREFERRED STOCK OF MYMD PHARMACEUTICALS, INC. PURSUANT TO SECTION 242 OF THE DELAWARE GENERAL CORPORATION LAW This Certificate of Amendment to the Amended and Restated Certificate of Designations of Series F Convertible Preferred Stock (the “Amendment”) is dated as of May 21, 2024. WHER

Form of Amendment to Series F Warrant, dated March 14, 2024, by and between TNF Pharmaceuticals, Inc. and the investors party thereto. (incorporated herein by reference to Exhibit 4.1 to the Company’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on May 15, 2024).

Exhibit 4.1 Amendment This Amendment (this “Amendment”), dated as of [ ], 2024, is by and among MyMD Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and each of the investors listed on the signature pages attached hereto (the “Investors”). WITNESSETH Whereas, the Company and the Investors are party to that certain Securities Purchase Agreement, dated as of February 21, 2023 (the “Pu

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36268 MyMD Phar

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 15, 2024 MyMD Pharmaceutica

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 15, 2024 MyMD Pharmaceuticals, Inc. (Exact name of Registrant as specified in its charter) Delaware 001-36268 22-2983783 (State or other jurisdiction of incorporation) (Commissi

Entry into a Material Definitive Agreement, Material Modification to Rights of Security Holders, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 5, 2024 MyMD Pharmaceuticals, Inc. (Exact name of Registrant as specified in its charter) Delaware 001-36268 22-2983783 (State or other jurisdiction of incorporation) (Commissio

Amended and Restated Certificate of Designations of Series F Convertible Preferred Stock of MyMD Pharmaceuticals, Inc. (incorporated herein by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on April 8, 2024).

Exhibit 3.1 Amended and Restated Certificate of Designations of Series F Convertible Preferred Stock of MyMD Pharmaceuticals, Inc. Pursuant to Section 242 of the Delaware General Corporation Law This Amended and Restated Certificate of Designations of Series F Convertible Preferred Stock (this “Amended and Restated Certificate of Designations”) is dated as of April 5, 2024 (the “Effective Date”).

Form of Omnibus Waiver and Amendment, dated April 5, 2024, by and between TNF Pharmaceuticals, Inc. and the investors party thereto (incorporated herein by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on April 8, 2024).

Exhibit 10.1 Omnibus Waiver and Amendment This Omnibus Waiver and Amendment (this “Agreement”), dated as of April , 2024, is by and among MyMD Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and each of the investors listed on the signature pages attached hereto (the “Investors”). WITNESSETH Whereas, the Company and the Investors are party to that certain Securities Purchase Agreeme

MyMD Pharmaceuticals, Inc. Compensation Recovery Policy

Exhibit 97.1 MyMD Pharmaceuticals, Inc. Compensation Recovery Policy This Compensation Recovery Policy (this “Policy”) of MyMD Pharmaceuticals, Inc. (the “Company”) is hereby adopted as of November 22, 2023 in compliance with Rule 5608 of the Nasdaq Rules. Certain terms used herein shall have the meanings set forth in “Section 3. Definitions” below. Section 1. Recovery Requirement Subject to Secti

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36268 MyMD Pharmaceutic

Description of Securities

Exhibit 4.1 DESCRIPTION OF SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXHANGE ACT OF 1934 This description of the capital stock of MyMD Pharmaceuticals, Inc., a Delaware corporation (“we,” “our” and the “Company”) is intended as a summary and is qualified in its entirety by reference to our certificate of incorporation (the “Certificate of Incorporation”) and the by-laws (the “

Seventh Amendment to Employment Agreement, dated September 6, 2023, by and between MyMD Pharmaceuticals, Inc. and Dr. Chris Chapman

Exhibit 10.58 SEVENTH AMENDMENT TO EMPLOYMENT AGREEMENT This SEVENTH AMENDMENT TO EMPLOYMENT AGREEMENT (this “Amendment”), is entered into as of September 8, 2023 (the “Effective Date”), by and between Chris Chapman, M.D. (“Employee”) and MyMD Pharmaceuticals, Inc. (the “Company”), for the purpose of amending that certain Employment Agreement, dated as of November 1, 2020, amended on December 18,

Certificate of Correction, dated March 25, 2024, to the Certificate of Incorporation of MyMD Pharmaceuticals, Inc., a Delaware corporation (incorporated herein by reference to Exhibit 3.3 to the Company’s Current Report on Form 8-K/A filed with the Securities and Exchange Commission on March 26, 2024).

Exhibit 3.3 CERTIFICATE OF CORRECTION OF MyMD Pharmaceuticals, Inc., a Delaware corporation MyMD Pharmaceuticals, Inc., a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the “Corporation”) hereby certifies: 1. The name of the Corporation is MyMD Pharmaceuticals, Inc. 2. The Certificate of Incorporation of the Corporation (the “Certifi

Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 4, 2024 MyMD Pharmaceuticals, Inc. (Exact name of Registrant as specified in its charter) Delaware 001-36268 22-2983783 (State or other jurisdiction of incor

Agreement and Plan of Merger, dated March 4, 2024, by and between MyMD Pharmaceuticals, Inc., a New Jersey corporation, and MyMD Pharmaceuticals, Inc., a Delaware corporation (incorporated herein by reference to Exhibit 2.1 to the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on March 7, 2024).

Exhibit 2.1 Agreement and Plan of Merger Between MyMD Pharmaceuticals, Inc., a New Jersey Corporation and MyMD Pharmaceuticals, Inc., a Delaware Corporation This Agreement and Plan of Merger (the “Agreement”), dated as of March 4, 2024, is made by and between MyMD Pharmaceuticals, Inc., a New Jersey corporation (the “Company”), and MyMD Pharmaceuticals, Inc. (d/b/a MyMD Sub, Inc.), a Delaware corp

Certificate of Incorporation of MyMD Pharmaceuticals, Inc., a Delaware corporation (incorporated herein by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on March 7, 2024).

Exhibit 3.1 Certificate of Incorporation of MyMD Pharmaceuticals, Inc. ARTICLE I The name of the corporation is MyMD Pharmaceuticals, Inc. (hereinafter referred to as the “Corporation”). ARTICLE II The address of the Corporation’s registered office is Corporation Trust Center, 1209 Orange St., Wilmington, New Castle County, Delaware 19801. The name of the registered agent at such address is The Co

Bylaws of MyMD Pharmaceuticals, Inc., a Delaware corporation (incorporated herein by reference to Exhibit 3.2 to the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on March 7, 2024).

Exhibit 3.2 BYLAWS OF MyMD Pharmaceuticals, Inc. A DELAWARE CORPORATION (Effective as of March 4, 2024) Table of Contents Table of Contents i Article I. Corporate Offices 1 Section 1.01 Registered Office. 1 Section 1.02 Other Offices. 1 Article II. Meetings of Stockholders 1 Section 2.01 Places of Meetings. 1 Section 2.02 Annual Meeting. 1 Section 2.03 Special Meeting 1 Section 2.04 Advance Notice

Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Entry into a Material Definitive Agreement, Material Modification to Rights of Security Holders, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 4, 2024 MyMD Pharmaceuticals, Inc. (Exact name of Registrant as specified in its charter) Delaware 001-36268 22-2983783 (State or other jurisdiction of incorporation) (Commissio

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 5, 2024 MyMD Pharmaceuticals, Inc. (Exact name of Registrant as specified in its charter) Delaware 001-36268 22-2983783 (State or other jurisdiction of incorporation) (Commissio

MyMD Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement for Continued Listing

Exhibit 99.1 MyMD Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement for Continued Listing BALTIMORE, MD – March 5, 2024 – MyMD Pharmaceuticals, Inc.® (Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage biopharmaceutical company committed to developing novel therapies for age-related diseases, autoimmune and inflammatory conditions, today announced that it received

MYMD / MyMD Pharmaceuticals, Inc. / Iroquois Capital Management, LLC Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2. (Amendment No. 5)* MyMD Pharmaceuticals, Inc. (Name of Issuer) Common Stock, no par value per share (Title of Class of Securities) 62856X102 (CUSIP Number) December 31, 2023

MYMD / MyMD Pharmaceuticals, Inc. / Global X Management CO LLC - ANNUAL SC 13G - POTX/MYMD PHARMACEUTICALS Passive Investment

SC 13G 1 annualsc13g-potxmymdpharma.htm ANNUAL SC 13G - POTX/MYMD PHARMACEUTICALS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G INFORMATION STATEMENT TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1 (b) (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2 (b) MyMD Pharmaceuticals, Inc. (Name of Issuer) Common Shares (Title of Class of Sec

MyMD Pharmaceuticals Announces Reverse Stock Split to Maintain Nasdaq Listing Common Stock Will Begin Trading on Split-Adjusted Basis on February 15, 2024

Exhibit 99.1 MyMD Pharmaceuticals Announces Reverse Stock Split to Maintain Nasdaq Listing Common Stock Will Begin Trading on Split-Adjusted Basis on February 15, 2024 BALTIMORE, MD – February 13, 2024 – MyMD Pharmaceuticals, Inc.® (Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage biopharmaceutical company committed to developing novel therapies for age-related diseases, autoimmune and in

Regulation FD Disclosure, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Material Modification to Rights of Security Holders, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 13, 2024 MyMD Pharmaceuticals, Inc (Exact name of Registrant as specified in its charter) New Jersey 001-36268 22-2983783 (State or other jurisdiction of incorporation) (Comm

Certificate of Amendment to the Amended and Restated Certificate of Incorporation, effective February 14, 2024 (incorporated herein by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on February 13, 2024).

Exhibit 3.1 New Jersey Division of Revenue CERTIFICATE OF AMENDMENT to the AMENDED AND RESTATED CERTIFICATE OF INCORPORATION (For Use by Domestic Profit Corporation) Pursuant to the provisions of Sections 14A:9-2(2), 14A:9-4(2), and 14A:7-15.1(3), Corporations, General, of the New Jersey Statutes, the undersigned corporation executes the following Certificate of Amendment to its Amended and Restat

MyMD Pharmaceuticals Plans FDA-Cleared Phase 2 Clinical Trial of MYMD-1 in Rheumatoid Arthritis Company targets first quarter 2024 for trial initiation Potential to be first orally-administered TNF-α inhibitor treatment for RA

Exhibit 99.1 MyMD Pharmaceuticals Plans FDA-Cleared Phase 2 Clinical Trial of MYMD-1 in Rheumatoid Arthritis Company targets first quarter 2024 for trial initiation Potential to be first orally-administered TNF-α inhibitor treatment for RA BALTIMORE—December 6, 2023 (BUSINESS WIRE)— MyMD Pharmaceuticals, Inc.® (Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage biopharmaceutical company com

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 6, 2023 MyMD Pharmaceuticals, Inc. (Exact name of Registrant as specified in its charter) New Jersey 001-36268 22-2983783 (State or other jurisdiction of incorporation) (Comm

Fourth Amendment to Employment Agreement, dated November 13, 2023, by and between MyMD Pharmaceuticals, Inc. and Dr. Adam Kaplin (incorporated herein by reference to Exhibit 10.3 to the Company’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 14, 2023).

Exhibit 10.3 fourTH AMENDMENT TO EMPLOYMENT AGREEMENT This fourTH AMENDMENT TO EMPLOYMENT AGREEMENT (this “Amendment”), is entered into as of November 13, 2023 (the “Effective Date”), by and between Adam Kaplin, M.D. (“Employee”) and MyMD Pharmaceuticals, Inc. (the “Company”), for the purpose of amending that certain Employment Agreement, dated as of December 18, 2020, amended on February 10, 2021

Eighth Amendment to Employment Agreement, dated November 13 2023, by and between MyMD Pharmaceuticals, Inc. and Dr. Chris Chapman (incorporated herein by reference to Exhibit 10.2 to the Company’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 14, 2023).

Exhibit 10.2 EIGHTH AMENDMENT TO EMPLOYMENT AGREEMENT This EIGHTH AMENDMENT TO EMPLOYMENT AGREEMENT (this “Amendment”), is entered into as of November 13, 2023 (the “Effective Date”), by and between Chris Chapman, M.D. (“Employee”) and MyMD Pharmaceuticals, Inc. (the “Company”), for the purpose of amending that certain Employment Agreement, dated as of November 1, 2020, amended on December 18, 202

First Amendment to Agreement, dated November 13, 2023, by and between MyMD Pharmaceuticals, Inc. and Christopher C. Schreiber (incorporated herein by reference to Exhibit 10.5 to the Company’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 14, 2023).

Exhibit 10.5 fIRST AMENDMENT TO AGREEMENT This first AMENDMENT TO executive chairman AGREEMENT (this “Amendment”), is entered into as of November 13, 2023 (the “Effective Date”), by and between Christopher C. Schreiber (“Employee”) and MyMD Pharmaceuticals, Inc. (formerly known as Akers Biosciences, Inc.) (the “Company”), for the purpose of amending that certain Executive Chairman Agreement, dated

Employment Mutual Separation Agreement, dated November 13, 2023, by and between MyMD Pharmaceuticals, Inc. and Paul M. Rivard.

Exhibit 10.4 EMPLOYMENT MUTUAL SEPARATION AGREEMENT THIS EMPLOYMENT MUTUAL SEPARATION AGREEMENT (this “Agreement”) is made and entered into as of the 13th day of November, 2023, by and between Paul M. Rivard, Esq. (“Employee”) and MyMD Pharmaceuticals, Inc. (“Company”). RECITALS: A. Pursuant to the Employment Agreement, dated September 21, 2020 and amended on November 24, 2020, December 18, 2020,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36268 MyMD Pha

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 19, 2023 MyMD Pharmaceuticals, Inc. (Exact name of Registrant as specified in its charter) New Jersey 001-36268 22-2983783 (State or other jurisdiction of incorporation) (Comm

MyMD Announces Preclinical Study Results Showing Novel Cannabidiol Analog, Supera-CBD™, Reduced Acute Inflammatory Pain

Exhibit 99.1 MyMD Announces Preclinical Study Results Showing Novel Cannabidiol Analog, Supera-CBD™, Reduced Acute Inflammatory Pain - Supera-CBD eased heat-related pain due to inflammation quickly and provided long-lasting pain relief lasting up to five hours - Results suggest Supera-CBD may target specific pain pathways, lessening the potential for side effects - MyMD was issued Japanese Patent

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 11, 2023 MyMD Pharmaceuticals, Inc. (Exact name of Registrant as specified in its charter) New Jersey 001-36268 22-2983783 (State or other jurisdiction of incorporation) (Comm

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 4, 2023 MyMD Pharmaceutic

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 4, 2023 MyMD Pharmaceuticals, Inc. (Exact name of Registrant as specified in its charter) New Jersey 001-36268 22-2983783 (State or other jurisdiction of incorporation) (Commi

MyMD Pharmaceuticals to Present Updated Statistically Significant Phase 2 Data for MYMD-1, Potential TNF-α Market Disrupter, at BioFuture 2023 - Company to share new positive, statistically significant results across Cohort 4 (1050mg) from Phase 2 st

Exhibit 99.1 MyMD Pharmaceuticals to Present Updated Statistically Significant Phase 2 Data for MYMD-1, Potential TNF-α Market Disrupter, at BioFuture 2023 - Company to share new positive, statistically significant results across Cohort 4 (1050mg) from Phase 2 study of MYMD-1 in sarcopenia, an age-related frailty disorder - BALTIMORE, MD – October 4, 2023 – MyMD Pharmaceuticals, Inc.® (Nasdaq: MYM

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 6, 2023 MyMD Pharmaceut

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 6, 2023 MyMD Pharmaceuticals, Inc. (Exact name of Registrant as specified in its charter) New Jersey 001-36268 22-2983783 (State or other jurisdiction of incorporation) (Com

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 14, 2023 MyMD Pharmaceuticals, Inc. (Exact name of Registrant as specified in its charter) New Jersey 001-36268 22-2983783 (State or other jurisdiction of incorporation) (Commi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36268 MyMD Pharmace

FDA Accepts MyMD Pharmaceuticals’ Investigational New Drug Application (IND) for Phase 2 Study of oral TNF-α inhibitor MYMD-1® in Rheumatoid Arthritis (RA) - Next-generation and first oral TNF-α inhibitor, which completed Phase 2 study for age-relate

Exhibit 99.1 FDA Accepts MyMD Pharmaceuticals’ Investigational New Drug Application (IND) for Phase 2 Study of oral TNF-α inhibitor MYMD-1® in Rheumatoid Arthritis (RA) - Next-generation and first oral TNF-α inhibitor, which completed Phase 2 study for age-related condition sarcopenia, represents a potentially groundbreaking advance in the treatment of RA and disruption of a $41 billion industry -

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 2, 2023 MyMD Pharmaceutica

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 2, 2023 MyMD Pharmaceuticals, Inc. (Exact name of Registrant as specified in its charter) New Jersey 001-36268 22-2983783 (State or other jurisdiction of incorporation) (Commis

Transcript of MyMD Pharmaceuticals, Inc. MyMD Pharmaceuticals Phase 2 Trial Update August 2, 2023

Exhibit 99.1 Transcript of MyMD Pharmaceuticals, Inc. MyMD Pharmaceuticals Phase 2 Trial Update August 2, 2023 Participants Joshua Silverman - Chairman, MyMD Pharmaceuticals, Inc. Chris Chapman - President, Director, and Chief Medical Officer, MyMD Pharmaceuticals, Inc. Adam Kaplin - Chief Scientific Officer, MyMD Pharmaceuticals, Inc. Presentation Operator Good day everyone, and welcome to the My

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 31, 2023 MyMD Pharmaceutical

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 31, 2023 MyMD Pharmaceuticals, Inc. (Exact name of Registrant as specified in its charter) New Jersey 001-36268 22-2983783 (State or other jurisdiction of incorporation) (Commiss

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 31, 2023 MyMD Pharmaceutical

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 31, 2023 MyMD Pharmaceuticals, Inc. (Exact name of Registrant as specified in its charter) New Jersey 001-36268 22-2983783 (State or other jurisdiction of incorporation) (Commiss

MyMD Pharmaceuticals Reports Statistically Significant Positive Topline Phase 2 Results for Next Generation Oral TNF-α Inhibitor MYMD-1® in Sarcopenia/Age-Related Frailty - MYMD-1 significantly reduced serum levels of chronic inflammatory markers and

Exhibit 99.1 MyMD Pharmaceuticals Reports Statistically Significant Positive Topline Phase 2 Results for Next Generation Oral TNF-α Inhibitor MYMD-1® in Sarcopenia/Age-Related Frailty - MYMD-1 significantly reduced serum levels of chronic inflammatory markers and met all primary pharmacokinetic and secondary safety and tolerability endpoints across multiple doses over 28 days of treatment - MYMD-1

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 14, 2023 MyMD Pharmaceutical

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 14, 2023 MyMD Pharmaceuticals, Inc. (Exact name of Registrant as specified in its charter) New Jersey 001-36268 22-2983783 (State or other jurisdiction of incorporation) (Commiss

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 9, 2023 MyMD Pharmaceuticals

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 9, 2023 MyMD Pharmaceuticals, Inc. (Exact name of Registrant as specified in its charter) New Jersey 001-36268 22-2983783 (State or other jurisdiction of incorporation) (Commissi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36268 MyMD Pharmac

Corporate Presentation, dated April 2023 (furnished herewith pursuant to Item 7.01)

Exhibit 99.2

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 12, 2023 MyMD Pharmaceutica

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 12, 2023 MyMD Pharmaceuticals, Inc. (Exact name of Registrant as specified in its charter) New Jersey 001-36268 22-2983783 (State or other jurisdiction of incorporation) (Commis

MyMD Pharmaceuticals® Provides Dosing Update on Phase 2 Multi-Center Clinical Trial of MYMD-1® as a Therapy for Delaying Aging and Extending Healthy Lifespan - Currently, there are no FDA-approved treatments for sarcopenia/frailty - - MyMD is only 3

Exhibit 99.1 MyMD Pharmaceuticals® Provides Dosing Update on Phase 2 Multi-Center Clinical Trial of MYMD-1® as a Therapy for Delaying Aging and Extending Healthy Lifespan - Currently, there are no FDA-approved treatments for sarcopenia/frailty - - MyMD is only 3 patients away from dosing its final patient in its first Phase 2 clinical trial of lead drug candidate MYMD-1® - BALTIMORE, MD – April 12

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 4, 2023 MyMD Pharmaceutical

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 4, 2023 MyMD Pharmaceuticals, Inc. (Exact name of Registrant as specified in its charter) New Jersey 001-36268 22-2983783 (State or other jurisdiction of incorporation) (Commiss

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36268 MyMD Pharmaceutic

Description of Securities

Exhibit 4.1 DESCRIPTION OF SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXHANGE ACT OF 1934 This description of the capital stock of MyMD Pharmaceuticals, Inc., a New Jersey corporation (“we,” “our” and the “Company”) is intended as a summary and is qualified in its entirety by reference to our amended and restated certificate of incorporation, as amended (the “Amended and Restat

List of Subsidiaries of MyMD Pharmaceuticals, Inc.

Exhibit 21.1 Subsidiaries of the Registrant1 Name of Company Jurisdiction of Organization Akers Acquisition Sub, Inc. New Jersey Bout Time Marketing Corporation New Jersey XYZ Merger Sub Inc. Florida 1 This information is as of March 29, 2023.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 22, 2023 MyMD Pharmaceutica

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 22, 2023 MyMD Pharmaceuticals, Inc. (Exact name of Registrant as specified in its charter) New Jersey 001-36268 22-2983783 (State or other jurisdiction of incorporation) (Commis

Third Amendment to Employment Agreement between Paul Rivard, Esq. and MyMD Pharmaceuticals, Inc., dated March 22, 2023. (incorporated herein by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on March 23, 2023).

Exhibit 10.1 Third AMENDMENT TO EMPLOYMENT AGREEMENT This third AMENDMENT TO EMPLOYMENT AGREEMENT (this “Amendment”), is entered into as of March 22, 2023 (the “Effective Date”), by and between Paul Rivard, Esq. (“Employee”) and MyMD Pharmaceuticals, Inc. (the “Company”), for the purpose of amending that certain Employment Agreement, dated as of September 21, 2020, and amended on November 24, 2020

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 22, 2023 MyMD Pharmaceutica

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 22, 2023 MyMD Pharmaceuticals, Inc. (Exact name of Registrant as specified in its charter) New Jersey 001-36268 22-2983783 (State or other jurisdiction of incorporation) (Commis

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 22, 2023 MyMD Pharmaceutica

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 22, 2023 MyMD Pharmaceuticals, Inc. (Exact name of Registrant as specified in its charter) New Jersey 001-36268 22-2983783 (State or other jurisdiction of incorporation) (Commis

MyMD Pharmaceuticals® and Charles River Present Positive Data for Next Generation, Oral TNF-α Inhibitor MYMD-1® in Rheumatoid Arthritis Preclinical results showed MYMD-1® significantly reduced histopathological changes and the severity of standard ar

Exhibit 99.1 MyMD Pharmaceuticals® and Charles River Present Positive Data for Next Generation, Oral TNF-α Inhibitor MYMD-1® in Rheumatoid Arthritis Preclinical results showed MYMD-1® significantly reduced histopathological changes and the severity of standard arthritis clinical trial measures compared to placebo; demonstrate future potential to disrupt the TNF-α inhibitor market BALTIMORE, MD– Ma

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 20, 2023 MyMD Pharmaceutica

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 20, 2023 MyMD Pharmaceuticals, Inc. (Exact name of Registrant as specified in its charter) New Jersey 001-36268 22-2983783 (State or other jurisdiction of incorporation) (Commis

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State

MyMD Joins LOT Network in Effort to Protect Company and Shareholders from Patent Trolls

Exhibit 99.1 MyMD Joins LOT Network in Effort to Protect Company and Shareholders from Patent Trolls BALTIMORE, MD – March 8, 2023 — MyMD Pharmaceuticals, Inc.® (Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage biopharmaceutical company developing groundbreaking therapies for the treatment of serious and debilitating autoimmune and inflammatory diseases, today announced that it has joined

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 8, 2023 MyMD Pharmaceutical

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 8, 2023 MyMD Pharmaceuticals, Inc. (Exact name of Registrant as specified in its charter) New Jersey 001-36268 22-2983783 (State or other jurisdiction of incorporation) (Commiss

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 2, 2023 MyMD Pharmaceutical

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 2, 2023 MyMD Pharmaceuticals, Inc. (Exact name of Registrant as specified in its charter) New Jersey 001-36268 22-2983783 (State or other jurisdiction of incorporation) (Commiss

MyMD Announces U.S. Drug Enforcement Administration (DEA) Determines Supera-CBD™ is not a Controlled Substance or Listed Chemical — DEA scientific review concludes Supera-CBD will not be classified as a regulated chemical or require scheduling during

Exhibit 99.1 MyMD Announces U.S. Drug Enforcement Administration (DEA) Determines Supera-CBD™ is not a Controlled Substance or Listed Chemical — DEA scientific review concludes Supera-CBD will not be classified as a regulated chemical or require scheduling during development — BALTIMORE, MD – March 2, 2023 — MyMD Pharmaceuticals, Inc.® (Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage bio

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 28, 2023 MyMD Pharmaceut

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 28, 2023 MyMD Pharmaceuticals, Inc. (Exact name of Registrant as specified in its charter) New Jersey 001-36268 22-2983783 (State or other jurisdiction of incorporation) (Com

MyMD Pharmaceuticals® Announces Upcoming Presentation of Preclinical Rheumatoid Arthritis Data for Oral TNF-α Inhibitor MYMD-1® at the Society of Toxicology 2023 Annual Meeting — Study results comparing the anti-inflammatory effects of MYMD-1® to Enb

Exhibit 99.1 MyMD Pharmaceuticals® Announces Upcoming Presentation of Preclinical Rheumatoid Arthritis Data for Oral TNF-α Inhibitor MYMD-1® at the Society of Toxicology 2023 Annual Meeting — Study results comparing the anti-inflammatory effects of MYMD-1® to Enbrel (etanercept) accepted for poster presentation — BALTIMORE, MD– February 28, 2023 – MyMD Pharmaceuticals, Inc.® (Nasdaq: MYMD) (“MyMD”

MyMD Pharmaceuticals, Inc. 15,000 Shares of Preferred Stock 6,651,885 Warrants to purchase an aggregate of 6,651,885 Shares of Common Stock (and the Shares of Common Stock issuable upon the conversion of such Preferred Stock and exercise of such Warr

Filed Pursuant to Rule 424(b)(5) Registration No. 333-254698 Prospectus Supplement (To prospectus dated May 11, 2021) MyMD Pharmaceuticals, Inc. 15,000 Shares of Preferred Stock 6,651,885 Warrants to purchase an aggregate of 6,651,885 Shares of Common Stock (and the Shares of Common Stock issuable upon the conversion of such Preferred Stock and exercise of such Warrants) We are offering 15,000 sha

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 21, 2023 MyMD Pharmaceut

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 21, 2023 MyMD Pharmaceuticals, Inc. (Exact name of Registrant as specified in its charter) New Jersey 001-36268 22-2983783 (State or other jurisdiction of incorporation) (Com

MyMD Announces $15 Million Offering with Existing Investors

Exhibit 99.1 MyMD Announces $15 Million Offering with Existing Investors BALTIMORE—February 21, 2023—MyMD Pharmaceuticals, Inc.® (Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage biopharmaceutical company developing groundbreaking therapies for the treatment of serious and debilitating autoimmune and inflammatory diseases, today announced that it has executed a securities purchase agreeme

Form of Certificate of Designations of Series F Convertible Preferred Stock (incorporated herein by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on February 21, 2023).

Exhibit 3.1 CERTIFICATE OF DESIGNATIONS OF SERIES F CONVERTIBLE PREFERRED STOCK OF MyMD PHARMACEUTICALS, INC. I, Chris Chapman, M.D., hereby certify that I am the President of MyMD Pharmaceuticals, Inc. (the “Company”), a corporation organized and existing under the New Jersey Business Corporation Act (the “BCA”), and further do hereby certify: That pursuant to the authority expressly conferred up

Engagement Letter, dated February 21, 2023 by and between MyMD Pharmaceuticals, Inc. and Katalyst Securities LLC

Exhibit 10.2 KATALYST SECURITIES LLC 630 THIRD AVENUE, 5TH FLOOR NEW YORK, NY 10017 TEL: 212-400-6993 FAX: 212-247-1059 Member: FINRA & SIPC February 21, 2023 STRICTLY CONFIDENTIAL MyMD Pharmaceuticals, Inc. 855 N. Wolfe Street, Suite 601 Baltimore, MD 21205 Ladies and Gentlemen: This letter (the “Agreement”) constitutes our understanding with respect to the engagement of Katalyst Securities LLC (

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 21, 2023 MyMD Pharmaceut

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 21, 2023 MyMD Pharmaceuticals, Inc. (Exact name of Registrant as specified in its charter) New Jersey 001-36268 22-2983783 (State or other jurisdiction of incorporation) (Com

Form of Purchase Agreement (incorporated herein by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on February 21, 2023).

Exhibit 10.1 Securities Purchase Agreement This Securities Purchase Agreement (the “Agreement”), dated as of , 2023, is by and among MyMD Pharmaceuticals, Inc., a New Jersey corporation (the “Company”), and each of the investors listed on the Schedule of Buyers attached hereto (individually, a “Buyer” and collectively, the “Buyers”). RECITALS A. The Company has authorized, subject to acceptance of

Form of Warrant (incorporated herein by reference to Exhibit 4.1 to the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on February 21, 2023).

Exhibit 4.1 Form of Warrant MyMD Pharmaceuticals, Inc. Warrant To Purchase Common Stock Warrant No.: Date of Issuance: [●], 2023 (“Issuance Date”) MyMD Pharmaceuticals, Inc., a New Jersey corporation (the “Company”), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, , the registered holder hereof or its permitted assigns (the

MYMD / MyMD Pharmaceuticals, Inc. / Iroquois Capital Management, LLC Passive Investment

SC 13G/A 1 c105644sch13ga.htm SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2. (Amendment No. 4)* MyMD Pharmaceuticals, Inc. (Name of Issuer) Common Stock, no par value per share (Title of Class of Securities) 62856X102 (C

Sixth Amendment to Employment Agreement between Chris Chapman and MyMD Pharmaceuticals, Inc., dated January 1, 2023 (incorporated herein by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on February 3, 2023).

Exhibit 10.1 SIXTH AMENDMENT TO EMPLOYMENT AGREEMENT This sixth AMENDMENT TO EMPLOYMENT AGREEMENT (this “Amendment”), is entered into as of January 1, 2023 (the “Effective Date”), by and between Chris Chapman, M.D. (“Employee”) and MyMD Pharmaceuticals, Inc. (the “Company”), for the purpose of amending that certain Employment Agreement, dated as of November 1, 2020, and as amended on December 18,

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 1, 2023 MyMD Pharmaceuticals, Inc. (Exact name of Registrant as specified in its charter) New Jersey 001-36268 22-2983783 (State or other jurisdiction of incorporation) (Comm

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 14, 2022 MyMD Pharmaceuticals, Inc. (Exact name of Registrant as specified in its charter) New Jersey 001-36268 22-2983783 (State or other jurisdiction of incorporation) (Com

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 6, 2022 MyMD Pharmaceuti

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 6, 2022 MyMD Pharmaceuticals, Inc. (Exact name of Registrant as specified in its charter) New Jersey 001-36268 22-2983783 (State or other jurisdiction of incorporation) (Comm

MyMD Pharmaceuticals® to Present Data on Oral TNF-a Inhibitor MYMD-1® at the British Society for Immunology (BSI) Congress 2022

Exhibit 99.1 MyMD Pharmaceuticals® to Present Data on Oral TNF-a Inhibitor MYMD-1® at the British Society for Immunology (BSI) Congress 2022 - Preclinical and early clinical studies of MYMD-1®, an oral, small-molecule, selective TNF-α inhibitor, suggest future potential to disrupt the Rheumatoid Arthritis market - BALTIMORE, MD – December 6, 2022 – MyMD Pharmaceuticals, Inc.® (Nasdaq: MYMD) (“MyMD

MyMD Pharmaceuticals® Announces Upcoming Presentation of Late-Breaking Data for MYMD-1® at the 2022 British Society for Immunology (BSI) Congress

Exhibit 99.1 MyMD Pharmaceuticals? Announces Upcoming Presentation of Late-Breaking Data for MYMD-1? at the 2022 British Society for Immunology (BSI) Congress - Preclinical and early clinical studies of MYMD-1?, an oral, small-molecule, selective TNF-? inhibitor accepted for presentation - BALTIMORE, MD ? November 17, 2022 ? MyMD Pharmaceuticals, Inc.? (Nasdaq: MYMD) (?MyMD? or ?the Company?), a c

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 17, 2022 MyMD Pharmaceuticals, Inc. (Exact name of Registrant as specified in its charter) New Jersey 001-36268 22-2983783 (State or other jurisdiction of incorporation) (Com

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2022 MyMD Pharmaceut

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2022 MyMD Pharmaceuticals, Inc. (Exact name of Registrant as specified in its charter) New Jersey 001-36268 22-2983783 (State or other jurisdiction of incorporation) (Com

MyMD Pharmaceuticals Announces Publication of Phase 1 Data for oral TNF-alpha Inhibitor MYMD-1® in Peer-Reviewed Journal Data Research MYMD-1 demonstrated favorable safety and tolerability profile across multiple doses, with no clinically relevant ad

Exhibit 99.1 MyMD Pharmaceuticals Announces Publication of Phase 1 Data for oral TNF-alpha Inhibitor MYMD-1® in Peer-Reviewed Journal Data Research MYMD-1 demonstrated favorable safety and tolerability profile across multiple doses, with no clinically relevant adverse events, supporting advancement of the compound for Sarcopenia and Rheumatoid Arthritis BALTIMORE, MD. – November 14, 2022 – MyMD Ph

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: September 30, 2022 ☐ TRANSITION REPORT PURSUAN

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: September 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-36268 MyMD Pharmaceutical

Fifth Amendment to Employment Agreement between Chris Chapman and MyMD Pharmaceuticals, Inc., dated August 30, 2022 (incorporated herein by reference to Exhibit 10.2 to the Company’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 10, 2022).

Exhibit 10.2 Fifth AMENDMENT TO EMPLOYMENT AGREEMENT This fifth AMENDMENT TO EMPLOYMENT AGREEMENT (this ?Amendment?), is entered into as of August 30, 2022 (the ?Effective Date?), by and between Chris Chapman, M.D. (?Employee?) and MyMD Pharmaceuticals, Inc. (the ?Company?), for the purpose of amending that certain Employment Agreement, dated as of November 1, 2020, and as amended on December 18,

Third Amendment to Employment Agreement between Adam Kaplin and MyMD Pharmaceuticals, Inc., dated August 30, 2022 (incorporated herein by reference to Exhibit 10.2 to the Company’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 10, 2022).

Exhibit 10.3 Third AMENDMENT TO EMPLOYMENT AGREEMENT This third AMENDMENT TO EMPLOYMENT AGREEMENT (this ?Amendment?), is entered into as of August 30, 2022 (the ?Effective Date?), by and between Adam Kaplin, M.D. (?Employee?) and MyMD Pharmaceuticals, Inc. (the ?Company?), for the purpose of amending that certain Employment Agreement, dated as of December 18, 2020, and as amended on February 10, 2

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 20, 2022 MyMD Pharmaceuticals, Inc. (Exact name of Registrant as specified in its charter) New Jersey 001-36268 22-2983783 (State or other jurisdiction of incorporation) (Co

MyMD Pharmaceuticals® Provides Dosing Update on Phase 2 Multi-Center Clinical Trial of MYMD-1® as a Therapy for Delaying Aging and Extending Healthy Lifespan Efficacy data anticipated in Q4 of 2022

Exhibit 99.1 MyMD Pharmaceuticals? Provides Dosing Update on Phase 2 Multi-Center Clinical Trial of MYMD-1? as a Therapy for Delaying Aging and Extending Healthy Lifespan Efficacy data anticipated in Q4 of 2022 BALTIMORE, MD ? September 20, 2022 ? MyMD Pharmaceuticals, Inc.? (Nasdaq: MYMD) (?MyMD? or ?the Company?), a clinical stage biopharmaceutical company developing groundbreaking therapies for

MYMD / MyMD Pharmaceuticals, Inc. / DUFFEY SAMUEL S Activist Investment

SC 13D 1 hjw1.htm CUSIP No. 62856X102 Page 1 of 7 Pages UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 MYMD PHARMACEUTICALS, INC. (Name of Issuer) Common Stock, no par value (Title of Class of Securities) 62856X102 (CUSIP Number) Samuel Duffey 8771 Grey Oaks Ave. Sarasota, Florida 34238 941-400-4788 (Name, Address and

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 30, 2022 MyMD Pharmaceuticals, Inc. (Exact name of Registrant as specified in its charter) New Jersey 001-36268 22-2983783 (State or other jurisdiction of incorporation) (Commi

MYMD PHARMACEUTICALS RECEIVES GRANT FROM EUROPEAN PATENT OFFICE FOR SUPERA-CBD™ COMPOUND ALLOWED CLAIMS COVER SUPERA-CBD™ AS A NEW MOLECULAR ENTITY AND PHARMACEUTICAL FORMULATIONS CONTAINING THE COMPOUND

Exhibit 99.1 MYMD PHARMACEUTICALS RECEIVES GRANT FROM EUROPEAN PATENT OFFICE FOR SUPERA-CBD? COMPOUND ALLOWED CLAIMS COVER SUPERA-CBD? AS A NEW MOLECULAR ENTITY AND PHARMACEUTICAL FORMULATIONS CONTAINING THE COMPOUND BALTIMORE, MD. ? August 30, 2022 ? MyMD Pharmaceuticals, Inc.? (Nasdaq: MYMD) (?MyMD?), a clinical stage pharmaceutical company committed to developing novel therapies for age-related

1,411,764 Shares of Common Stock MyMD Pharmaceuticals, Inc.

Filed Pursuant to Rule 424(b)(5) Registration No. 333-254698 Prospectus Supplement (To prospectus dated May 11, 2021) 1,411,764 Shares of Common Stock MyMD Pharmaceuticals, Inc. We are offering 1,411,764 shares of our common stock pursuant to this prospectus supplement and accompanying prospectus to certain accredited and institutional investors. Each share of common stock is being sold at a price

Entry into a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 15, 2022 MyMD Pharmaceuticals, Inc. (Exact name of Registrant as specified in its charter) New Jersey 001-36268 22-2983783 (State or other jurisdiction of incorporation) (Commi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: June 30, 2022 ☐ TRANSITION REPORT PURSUANT TO

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-36268 MyMD Pharmaceuticals, In

Form of Securities Purchase Agreement (incorporated herein by reference to Exhibit 10.1 to the Company’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 15, 2022).

Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this ?Agreement?) is dated as of August 15, 2022, between MyMD Pharmaceuticals, Inc., a New Jersey corporation (the ?Company?), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a ?Purchaser? and collectively the ?Purchasers?). WHEREAS, subject to the terms and cond

Form of Warrant (incorporated herein by reference to Exhibit 4.1 to the Company’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 15, 2022).

Exhibit 4.1 EXHIBIT A NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM R EGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECT

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 3, 2022 MyMD Pharmaceuticals, Inc. (Exact name of Registrant as specified in its charter) New Jersey 001-36268 22-2983783 (State or other jurisdiction of incorporation) (Commis

Data Showing MyMD Pharmaceuticals’ MYMD-1® May Extend Life and Improve Health Published in the Journal of Gerontology: Biological Sciences Study of oral TNF-α inhibitor MYMD-1 demonstrates significant improvements in lifespan and maintenance of healt

Exhibit 99.1 Data Showing MyMD Pharmaceuticals’ MYMD-1® May Extend Life and Improve Health Published in the Journal of Gerontology: Biological Sciences Study of oral TNF-α inhibitor MYMD-1 demonstrates significant improvements in lifespan and maintenance of health characteristics compared to rapamycin BALTIMORE, MD. – August 3, 2022 – MyMD Pharmaceuticals, Inc.® (Nasdaq: MYMD) (“MyMD” or “the Comp

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 26, 2022 MyMD Pharmaceuticals, Inc. (Exact name of Registrant as specified in its charter) New Jersey 001-36268 22-2983783 (State or other jurisdiction of incorporation) (Commiss

MyMD Pharmaceuticals® Advances Phase 2 Multi-Center Clinical Trial of MYMD-1® as a Therapy for Delaying Aging and Extending Healthy Lifespan Sarcopenia trial shows no evidence of toxicity or safety issues and patients were enrolled in the next higher

Exhibit 99.1 MyMD Pharmaceuticals? Advances Phase 2 Multi-Center Clinical Trial of MYMD-1? as a Therapy for Delaying Aging and Extending Healthy Lifespan Sarcopenia trial shows no evidence of toxicity or safety issues and patients were enrolled in the next higher dose of MYMD-1 BALTIMORE, MD. ? July 26, 2022 ? MyMD Pharmaceuticals, Inc.? (Nasdaq: MYMD) (?MyMD? or ?the Company?), a clinical stage p

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 12, 2022 MyMD Pharmaceuticals, Inc. (Exact name of Registrant as specified in its charter) New Jersey 001-36268 22-2983783 (State or other jurisdiction of incorporation) (Commiss

MyMD Pharmaceuticals to Collaborate with Bascom Palmer Eye Institute to Study MYMD-1 in Ophthalmic Conditions Bascom Palmer Eye Institute ranked the #1 eye hospital in the United States for 20 years in a row by U.S. News & World Report

Exhibit 99.1 MyMD Pharmaceuticals to Collaborate with Bascom Palmer Eye Institute to Study MYMD-1 in Ophthalmic Conditions Bascom Palmer Eye Institute ranked the #1 eye hospital in the United States for 20 years in a row by U.S. News & World Report BALTIMORE, MD. ? July 12, 2022 ? MyMD Pharmaceuticals, Inc.? (Nasdaq: MYMD) (?MyMD? or ?the Company?), a clinical stage pharmaceutical company committe

Filing Fee Table

EX-FILING FEES 4 ex107.htm Exhibit 107 Calculation of Filing Fee Table Form S-8 MyMD Pharmaceuticals, Inc. Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee (2) Equity Common Stock, no par value per share Rule 457(h) 227,987 (3) $ 4.48 (4) $ 1,021,381.76 $ 0.0000

As filed with the Securities and Exchange Commission on July 5, 2022

As filed with the Securities and Exchange Commission on July 5, 2022 Registration No.

MyMD Pharmaceuticals Advances Phase 2 Multi-Center Clinical Trial of MYMD-1 as a Therapy for Delaying Aging and Extending Healthy Lifespan Efficacy data expected in second half of 2022

Exhibit 99.1 MyMD Pharmaceuticals Advances Phase 2 Multi-Center Clinical Trial of MYMD-1 as a Therapy for Delaying Aging and Extending Healthy Lifespan Efficacy data expected in second half of 2022 BALTIMORE, MD. ? June 21, 2022 ? MyMD Pharmaceuticals, Inc.? (Nasdaq: MYMD) (?MyMD? or ?the Company?), a clinical stage pharmaceutical company committed to extending healthy lifespan, today announced fu

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 21, 2022 MyMD Pharmaceuticals, Inc. (Exact name of Registrant as specified in its charter) New Jersey 001-36268 22-2983783 (State or other jurisdiction of incorporation) (Commiss

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: March 31, 2022 ☐ TRANSITION REPORT PURSUANT TO

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-36268 MyMD Pharmaceuticals, I

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 12, 2022 MyMD Pharmaceuticals, Inc. (Exact name of Registrant as specified in its charter) New Jersey 001-36268 22-2983783 (State or other jurisdiction of incorporation) (Commis

MyMD Pharmaceuticals’ Lead Compound MYMD-1 Demonstrates Superior Anti-inflammatory Effects over Top-Selling Therapies in a Pivotal Preclinical Model of Rheumatoid Arthritis MyMD seeks to disrupt the $31 billion global market for rheumatoid arthritis

Exhibit 99.1 MyMD Pharmaceuticals’ Lead Compound MYMD-1 Demonstrates Superior Anti-inflammatory Effects over Top-Selling Therapies in a Pivotal Preclinical Model of Rheumatoid Arthritis MyMD seeks to disrupt the $31 billion global market for rheumatoid arthritis (RA) drug therapies with MYMD-1, which could potentially prove safer, more effective and better tolerated than current options Submission

Exhibit 4.1

Exhibit 4.1 DESCRIPTION OF SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXHANGE ACT OF 1934 As of March 31, 2022, MyMD Pharmaceuticals, Inc., a New Jersey corporation (?we,? ?our? and the ?Company?) has our common stock, no par value per share registered under Section 12 of the Securities Exchange Act of 1934, as amended. The description of our capital stock included herein is in

List of Subsidiaries of MyMD Pharmaceuticals, Inc.

Exhibit 21.1 Subsidiaries of the Registrant1 Name of Company Jurisdiction of Organization Akers Acquisition Sub, Inc. New Jersey Bout Time Marketing Corporation New Jersey MyMD Pharmaceuticals (Florida), Inc. Florida XYZ Merger Sub Inc. Florida 1 This information is as of March 31, 2022.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36268 MyMD Pharmaceutic

Form of Placement Agent Warrant Certificate (incorporated herein by reference to Exhibit 4.12 to the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 31, 2022).

Exhibit 4.12 PLACEMENT AGENT COMMON STOCK PURCHASE WARRANT Akers Biosciences, Inc. Warrant Shares: Issue Date: December 9, 2019 Initial Exercise Date: December 9, 2019 THIS PLACEMENT AGENT COMMON STOCK PURCHASE WARRANT (the ?Warrant?) certifies that, for value received, or its assigns (the ?Holder?) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinaft

Amendment No. 4 to Employment Agreement between Chris Chapman and MyMD Pharmaceuticals, Inc., dated November 24, 2021 (incorporated herein by reference to Exhibit 10.66 to the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 31, 2022).

Exhibit 10.66 Fourth AMENDMENT TO EMPLOYMENT AGREEMENT This fourth AMENDMENT TO EMPLOYMENT AGREEMENT (this ?Amendment?), is entered into as of November 24, 2021 (the ?Effective Date?), by and between Chris Chapman, M.D. (?Employee?) and MYMD Pharmaceuticals, Inc. (the ?Company?), for the purpose of amending that certain Employment Agreement, dated as of November 1, 2020, and as amended on December

Amendment No. 2 to Employment Agreement between Adam Kaplin and MyMD Pharmaceuticals, Inc., dated November 24, 2021 (incorporated herein by reference to Exhibit 10.67 to the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 31, 2022).

Exhibit 10.67 Second AMENDMENT TO EMPLOYMENT AGREEMENT This Second AMENDMENT TO EMPLOYMENT AGREEMENT (this ?Amendment?), is entered into as of November 24, 2021 (the ?Effective Date?), by and between Adam Kaplin, M.D. (?Employee?) and MYMD Pharmaceuticals, Inc. (the ?Company?), for the purpose of amending that certain Employment Agreement, dated as of December 18, 2020, and as amended on February

MyMD Pharmaceuticals Enrolls First Patient in Phase 2 Clinical Trial of MYMD-1 as a Therapy for Delaying Aging and Extending Healthy Lifespan Efficacy data from fully funded Phase 2 trial is expected in first half of 2022

Exhibit 99.1 MyMD Pharmaceuticals Enrolls First Patient in Phase 2 Clinical Trial of MYMD-1 as a Therapy for Delaying Aging and Extending Healthy Lifespan Efficacy data from fully funded Phase 2 trial is expected in first half of 2022 BALTIMORE, MD. ? February 23, 2022 ? MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD) (?MyMD? or ?the Company?), a clinical stage pharmaceutical company committed to extend

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 23, 2022 MyMD Pharmaceuticals, Inc. (Exact name of Registrant as specified in its charter) New Jersey 001-36268 22-2983783 (State or other jurisdiction of incorporation) (Com

MYMD / MyMD Pharmaceuticals, Inc. / Iroquois Capital Management, LLC Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO ? 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO ? 240.13d-2. (Amendment No. 3)* MyMD Pharmaceuticals, Inc. (Name of Issuer) Common Stock, no par value per share (Title of Class of Securities) 62856X102 (CUSIP Number) December 31, 2021

MYMD / MyMD Pharmaceuticals, Inc. / INTRACOASTAL CAPITAL, LLC - AMENDMENT NO. 2 TO SCHEDULE 13G Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* MyMD Pharmaceuticals, Inc. (Name of Issuer) Common Stock, no par value per share (Title of Class of Securities) 62856X102 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the

MyMD Pharmaceuticals Announces Positive Clinical Data in Advance of Upcoming Phase 2 Trial of MYMD-1 for Extending Healthy Lifespan

Exhibit 99.1 MyMD Pharmaceuticals Announces Positive Clinical Data in Advance of Upcoming Phase 2 Trial of MYMD-1 for Extending Healthy Lifespan ? Phase 1 dose-ranging study results meet primary endpoints ? Drug demonstrates statistically significant efficacy in reducing levels of the root cause of aging, TNF-?, in the blood ? Data from fully funded Phase 2 trial anticipated in first half of 2022

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 8, 2022 MyMD Pharmaceuticals, Inc. (Exact name of Registrant as specified in its charter) New Jersey 001-36268 22-2983783 (State or other jurisdiction of incorporation) (Comm

MYMD / MyMD Pharmaceuticals, Inc. / MAINFIELD ENTERPRISES INC - SC 13G/A Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.

JOINT FILING AGREEMENT

Exhibit 99.1 JOINT FILING AGREEMENT This joint filing agreement (this ?Agreement?) is made and entered into as of this 11th day of January 2022, by and among Mainfield Enterprises Inc., Trumano International Inc., Enright Holding Corp., Mercury Advisory Limited (UK) and Eli Gabso. The parties to this Agreement hereby acknowledge and agree that the foregoing statement on Amendment No. 1 to Schedule

MyMD Pharmaceuticals Announces Issuance of New U.S. Patent Covering MYMD-1 in a Method of Treating Sarcopenia Expands intellectual property portfolio for lead drug candidate MYMD-1 to 3 U.S. patents related to aging and extending healthy lifespan, 16

Exhibit 99.1 MyMD Pharmaceuticals Announces Issuance of New U.S. Patent Covering MYMD-1 in a Method of Treating Sarcopenia Expands intellectual property portfolio for lead drug candidate MYMD-1 to 3 U.S. patents related to aging and extending healthy lifespan, 16 patents in total BALTIMORE, MD. ? January 5, 2022 ? MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD) (?MyMD? or ?the Company?), a clinical stag

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 5, 2022 MyMD Pharmaceuticals, Inc. (Exact name of Registrant as specified in its charter) New Jersey 001-36268 22-2983783 (State or other jurisdiction of incorporation) (Commi

Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 29, 2021 MyMD Pharmaceuticals, Inc. (Exact name of Registrant as specified in its charter) New Jersey 001-36268 22-2983783 (State or other jurisdiction of incorporation) (Com

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (As Permitted by Rule 14a-6(e)(2)) ☐ Definitive

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State

Shareholder Letter, Winter 2021 (furnished herewith pursuant to Item 7.01)

Exhibit 99.1

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 3, 2021 MyMD Pharmaceuticals, Inc. (Exact name of Registrant as specified in its charter) New Jersey 001-36268 22-2983783 (State or other jurisdiction of incorporation) (Comm

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934

DEF 14A 1 formdef14-a.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 16, 2021 MyMD Pharmaceuticals, Inc. (Exact name of Registrant as specified in its charter) New Jersey 001-36268 22-2983783 (State or other jurisdiction of incorporation) (Com

MyMD Pharmaceuticals Receives FDA IND Clearance to Begin Phase 2 Trial of MYMD-1 for Extending Healthy Lifespan Believed to be the only IND application ever cleared by the FDA for a Phase 2 trial of a patented drug for delaying aging Phase 2 trial re

Exhibit 99.1 MyMD Pharmaceuticals Receives FDA IND Clearance to Begin Phase 2 Trial of MYMD-1 for Extending Healthy Lifespan Believed to be the only IND application ever cleared by the FDA for a Phase 2 trial of a patented drug for delaying aging Phase 2 trial recruiting begins immediately; efficacy data expected by the end of the first quarter of 2022 BALTIMORE, MD. ? November 16, 2021 ? MyMD Pha

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A Amendment No. 1

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A Amendment No. 1 ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-36268 M

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-36268 MyMD Pharmaceutical

Shareholder Director Nominations

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 12, 2021 MyMD Pharmaceuticals, Inc. (Exact name of Registrant as specified in its charter) New Jersey 001-36268 22-2983783 (State or other jurisdiction of incorporation) (Com

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 26, 2021 MyMD Pharmaceuticals, Inc. (Exact name of Registrant as specified in its charter) New Jersey 001-36268 22-2983783 (State or other jurisdiction of incorporation) (Comm

MyMD Pharmaceuticals President Chris Chapman, M.D. Named Medical Honoree of the Year by the Arthritis Foundation MyMD’s lead drug candidate, MYMD-1, is being developed to target aging and related diseases along with autoimmune diseases including rheu

Exhibit 99.1 MyMD Pharmaceuticals President Chris Chapman, M.D. Named Medical Honoree of the Year by the Arthritis Foundation MyMD?s lead drug candidate, MYMD-1, is being developed to target aging and related diseases along with autoimmune diseases including rheumatoid arthritis BALTIMORE, MD. ? October 26, 2021 ? MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD) (?MyMD? or ?the Company?), a clinical stag

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 19, 2021 MyMD Pharmaceuticals, Inc. (Exact name of Registrant as specified in its charter) New Jersey 001-36268 22-2983783 (State or other jurisdiction of incorporation) (Comm

MyMD Pharmaceuticals to Discuss its Novel Therapies for Aging and Related Diseases at the Dawson James Securities 6th Annual Small Cap Growth Conference on October 21 MyMD is pursuing high value opportunities in a massive healthcare market with no kn

Exhibit 99.1 MyMD Pharmaceuticals to Discuss its Novel Therapies for Aging and Related Diseases at the Dawson James Securities 6th Annual Small Cap Growth Conference on October 21 MyMD is pursuing high value opportunities in a massive healthcare market with no known competing FDA-approved drugs for treating aging disorders and extending healthy lifespan BALTIMORE, MD. ? October 19, 2021 ? MyMD Pha